Thid-party purchasers of the Stelara drug won partial class action certification in a case accusing Johnson & Johnson of delaying less expensive versions of the medication that treats Crohn’s disease.

(Reuters) - Johnson & Johnson's Stelara psoriasis drug has shown effectiveness against Crohn's disease in a second late-stage trial, the company said on Friday, bolstering prospects of its approval ...

Johnson & Johnson JNJ faces several challenges, like potential losses from expiring drug patents, ongoing legal battles ...

Johnson & Johnson’s (NYSE:JNJ) Stelara could become the #2 drug in the Crohn’s Disease market over the next few years. Crohn’s Disease causes inflammation of the digestive tract. J&J’s top selling ...

Johnson & Johnson said on Monday that the Food and Drug Administration approved the company's blockbuster psoriasis drug, Stelara, for use in adults with Crohn's disease. The drug is approved in the ...

(Reuters) - Johnson & Johnson's legal settlement with Amgen Inc to delay a biosimilar version of its blockbuster psoriasis treatment Stelara until January 2025 could make the drug a larger contributor ...

Medicare and its beneficiaries are paying significantly more for Stelara, Johnson & Johnson’s (NYSE:JNJ) popular biologic drug used to treat autoimmune diseases when obtained through pharmacies rather ...

Following the successful Phase 2 trial of experimental lupus drug Stelara® (ustekinumab), researchers returned to the study data to uncover just how the treatment works. As previously reported, Phase ...

Stelara is one of Johnson & Johnson's fastest growing drugs - and its just getting started. Even with the recent success there is no time to rest on laurels in the highly competitive landscape of ...

Johnson & Johnson’s (NYSE:JNJ) Stelara could become the #2 drug in the Crohn’s Disease market over the next few years. Crohn’s Disease causes inflammation of the digestive tract. J&J’s top selling ...